Clinical Trials for Legend Biotech

Explore 17 clinical trials worldwide

Showing 1-17 of 17 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Legend Biotech

Clinical Trials (17)

NCT07095075
A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
EARLY_PHASE1Not yet recruiting
36 participants
Started: Sep 20, 2025 · Completed: Dec 31, 2029
1 condition1 sponsor5 locations
NCT07100067
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
NANot yet recruiting
35 participants
Started: Aug 20, 2025 · Completed: Nov 20, 2029
1 condition2 sponsors4 locations
NCT07049081
A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases
PHASE1Recruiting
42 participants
Started: Jul 17, 2025 · Completed: Apr 30, 2030
1 condition1 sponsor6 locations
NCT06869278
A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
PHASE1Recruiting
37 participants
Started: Jun 17, 2025 · Completed: Dec 31, 2029
4 conditions2 sponsors3 locations
NCT07002112
The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies
PHASE1Recruiting
30 participants
Started: May 23, 2025 · Completed: Jun 30, 2029
1 condition2 sponsors6 locations
NCT06653556
A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus
EARLY_PHASE1Recruiting
34 participants
Started: Jan 8, 2025 · Completed: Sep 30, 2029
1 condition3 sponsors1 location
NCT06494371
A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
PHASE1Recruiting
32 participants
Started: Jul 31, 2024 · Completed: Aug 31, 2028
2 conditions2 sponsors1 location
NCT06472479
LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
NANot yet recruiting
66 participants
Started: Jul 1, 2024 · Completed: Oct 12, 2029
1 condition2 sponsors4 locations
NCT06395870
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
PHASE1Recruiting
33 participants
Started: May 9, 2024 · Completed: Jun 30, 2028
2 conditions2 sponsors2 locations
NCT06295549
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
PHASE1Recruiting
33 participants
Started: Apr 11, 2024 · Completed: Jun 30, 2028
1 condition2 sponsors3 locations
NCT06313957
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
PHASE1Recruiting
42 participants
Started: Mar 14, 2024 · Completed: Sep 30, 2028
2 conditions4 sponsors3 locations
NCT06197178
A Study of LCAR-G08 in Subjects With Advanced Gastrointestinal Tumors Expressing Guanylyl Cyclase C (GCC)
PHASE1Recruiting
42 participants
Started: Dec 28, 2023 · Completed: Mar 31, 2028
1 condition2 sponsors2 locations
NCT05680922
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
PHASE1Recruiting
41 participants
Started: Jul 26, 2023 · Completed: Mar 31, 2028
2 conditions1 sponsor4 locations
NCT05539430
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
PHASE1Recruiting
56 participants
Started: Apr 18, 2023 · Completed: Dec 31, 2027
4 conditions1 sponsor8 locations
NCT05498545
Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma
PHASE1Not yet recruiting
34 participants
Started: Sep 30, 2022 · Completed: Mar 31, 2027
1 condition2 sponsors1 location
NCT04712864
Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma
PHASE1Active, not recruiting
50 participants
Started: Sep 13, 2021 · Completed: Dec 31, 2025
5 conditions1 sponsor4 locations
NCT03758417
A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
PHASE2Active, not recruiting
123 participants
Started: Jan 23, 2019 · Completed: Oct 20, 2025
1 condition2 sponsors11 locations